Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting Gram-positive bacteria. Acurx has no revenue and funds operations through equity offerings. Its lead candidate, ibezapolstat, is an oral antibiotic for Clostridioides difficile infection (CDI), a hospital-acquired bacterial infection of the colon affecting an estimated 500,000–600,000 patients annually in the U.S. Ibezapolstat works by inhibiting DNA polymerase IIIC, an enzyme essential for DNA replication in Gram-positive bacteria, while largely sparing beneficial gut microbes. This microbiome-sparing mechanism is believed to reduce CDI recurrence, which is a major clinical problem with existing treatments. Phase 2 results showed a 96% clinical cure rate with no recurrences among treated patients. Ibezapolstat holds FDA QIDP and Fast Track designations, and is ready to enter Phase 3 trials. Acurx's near-term priority is securing Phase 3 funding, either through a pharma partnership or government sources such as BARDA. If approved, Acurx intends to partner with a larger company for commercialization, receiving milestones and royalties rather than selling directly. Acurx also has an early-stage pipeline candidate, ACX-375C, a preclinical pol IIIC inhibitor targeting MRSA, VRE, drug-resistant Streptococcus pneumoniae, and anthrax. Acurx operates with four full-time employees and relies on contract research organizations and manufacturers.